Biotech of the week: Sanifit from Mallorca and its novel take on calcification disorders

30/10/2015 - 2 minutes

This week we say ciao to Milan and head South-West, across the Mediterranean Sea and say hola to the the largest island in the Balearic Islands archipelago, Mallorca. This island is famous for its picturesque white beaches, brilliant weather and being the main vacation destination for the younger generations. It is also home to our biotech of the week, Sanifit.

sanifit logo

City: Palma, Mallorca, Spain

Founded: 2004

Financial Data: €40M total raised (as of 10/2015)

Employees: +/- 13 (as of 10/2015)

CEO:

Mission: Laboratoris Sanifit is a biotech company that is primarily focused on treating patients with calcification disorders. Currently they are developing their lead product, SNF472, for the treatment of the orphan disease, calciphylaxis and vascular calcification in the End Stage Renal Disease (ESRD) population undergoing haemodialysis. This flagship drug works by selectively blocking the progression of pathological cardiovascular calcification through a novel mechanism.  In 2014, Sanifit concluded phase Ia studies with healthy volunteers and recently concluded a phase Ib/IIa study in haemodialysis patients.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member